GUERF News and Press, Guerbet SA

H1 2024 revenue Half-yearly activity H1 revenue: €419.2m, up 11.8% at CER 1 , including an acceleration in Q2 (+14.5%) This acceleration was driven by continued catch-up in the Americas, the normalisation of orders in France and MRI sales Annual targets conf...

The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol) with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over If approved by the European...

2023-09-21 23:05:26 ET More on Guerbet Historical earnings data for Guerbet Dividend scorecard for Guerbet Financial information for Guerbet For further details see: Guerbet reports 1H results

Half-year results 2023 Acceleration of activity Half-year revenue: €378.6 million, up 2.8% at CER 1 Strong acceleration of activity in the second quarter, up 6.7% at CER Profitability in line with expectations EBITDA for the first...

First-half 2023 revenue Acceleration of activity Half-year revenue: €378.6 million, up +2.8% at CER 1 , with a strong acceleration of activity in Q2, at +6.7% Very dynamic sales in Asia (+16.6% in H1 at CER) and EMEA (+7.8%), but down in the Americas (-15...

Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer Villepinte, 17 July 2023 : Guerbet (FR0000032526 GBT), a global specialist in contrast media and medical imaging solutions, is delighted to announce the success of its teams at the PI-CAI (Prostate Imagi...

Q1 2023 Revenue Quarterly activity • Revenue: €179.8 million, down slightly by 1.3% at CER • Dynamic activity in EMEA (+7.3% at CER), increase in Asia (+2.2% at CER), expected drop in the Americas (-17.1% at CER) Annual objectives reaffirmed ...

2022 annual results Activity Annual revenue: €753.3 million, up 2.9% (-1.1% at CER 1 ) Steady momentum in Asia and for Interventional Imaging; negative impact of production delays at the Raleigh site Profitability in line with expectations ...

2022 revenue Activity Annual revenue: €753.3 million, up +2.9% (-1.1% at CER 1 ); production lags at the Raleigh site weighed on activity Profitability 2022 EBITDA margin: confirmation of the announced range of 13% to 14% (excluding ex...

2023 Strategic Priorities Diagnostic Imaging : increase Elucirem TM sales and strengthen international positions Interventional Imaging : prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadma...